That CR was for acquisition of Azer-Cel, IMU are running 3 parallel clinical trials each with IP which has IND, Fast Track designation, path to registrational clinical trial and now ODD. We will know in 3-4 months whether the MC can rerate back to $1B as it's clearly undervalue given the IP owned by IMU so I'm not sure how you can compare the current expenditure and MC as clearly they ain't in the same league.
The stock was heavily shorted after it enter ASX 200 and it's still heavily shorted, it doesn't affect LT if they are investing on the fundamental and the shorting does allow us to accumulate at low price for longer period.
IMU Price at posting:
4.8¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)